RCS - Spexis AG - Strategy Update and 2021 Financial Results
09/03/2022 08:30
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220309:nRSI1632Ea&default-theme=true
RNS Number : 1632E Spexis AG 09 March 2022
Spexis AG / Key word(s): Annual Results
Spexis to present strategy update and full-year 2021 financial results on
March 24, 2022
09-March-2022
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, March 9, 2022
Spexis to present strategy update and full-year 2021 financial results on
March 24, 2022
Spexis AG (SIX: SPEX) announced today that it will publish its full-year
financial results for 2021 on March 24 at 7.30am CET.
Jeffrey D. Wager, M.D. (CEO & Chairman) and Hernan Levett (CFO) will host
an earnings call at 2.30pm CET, together with Juergen Froehlich, M.D. (CMDO)
and Stephan Wehselau (COO). To access the earnings call, please use the
following details:
France: +33 (0)1 70 730 3 39
Germany: +49 (0)69 22222 5197
Italy: +39 02 3602 6066
Switzerland +41 (0)44 580 7279
United Kingdom +44 (0)330 165 4012
United States +1 646-828-8073
Event Title: Spexis AG - Strategy Update and 2021 Financial Results
Confirmation code: 4015509
The presentation will also be available via webcast:
https://www.webcast-eqs.com/spexis20220324
(https://che01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.webcast-eqs.com%2Fspexis20220324&data=04%7C01%7CHernan.Levett%40spexisbio.com%7Cc890ec0d7e13432ba6c508d9fdc5d491%7Cc13de0c0b4d3464c93a923fcbc19b97f%7C0%7C0%7C637819848427736353%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=XtkY0lfN%2BgGGKzb21D5awr4YULoKN0MKbe9Sq7fnSW4%3D&reserved=0)
Link for participants of the conference call (only slides, no audio, no
delay): https://www.webcast-eqs.com/spexis20220324/no-audio
(https://che01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.webcast-eqs.com%2Fspexis20220324%2Fno-audio&data=04%7C01%7CHernan.Levett%40spexisbio.com%7Cc890ec0d7e13432ba6c508d9fdc5d491%7Cc13de0c0b4d3464c93a923fcbc19b97f%7C0%7C0%7C637819848427736353%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=nX%2Bss5DeS7tSoG5ATzbCwPzgsI%2BS2XgvkctsPtw7Ux0%3D&reserved=0)
After the call, the presentation will be available via the above link.
For further information please contact:
For Investors: For Media:
Hernan Levett
Dr. Stephan Feldhaus
Chief Financial Officer
Feldhaus & Partner
Spexis AG.
+41 79 865 92 56
+41 61 567 16 00 feldhaus@feldhaus-partner.ch (mailto:feldhaus@feldhaus-partner.ch)
IR@spexisbio.com (mailto:IR@spexisbio.com)
About Spexis
Spexis is a clinical-stage biopharmaceutical company based in Allschwil,
Switzerland, focused on rare diseases and oncology. The current pipeline of
the company is a combination of two legacy companies, Polyphor AG and
EnBiotix, Inc. (Boston, MA, USA) which merged in December 2021. The combined
company has been renamed to Spexis AG and is trading on the SIX Swiss Exchange
under the symbol SIX:SPEX. For further information please visit:
www.spexisbio.com (http://www.spexisbio.com/) .
Disclaimer
This press release contains forward-looking statements which are based on
current assumptions and forecasts of Spexis management. Known and unknown
risks, uncertainties, and other factors could lead to material differences
between the forward-looking statements made here and the actual development,
in particular Spexis' results, financial situation, and performance. Readers
are cautioned not to put undue reliance on forward-looking statements, which
speak only of the date of this communication. Spexis disclaims any intention
or obligation to update and revise any forward-looking statements, whether as
a result of new information, future events or otherwise.
Additional features:
File: Spexis to announce FY2021 Financial Results
(https://eqs-cockpit.com/c/fncls.ssp?u=739492cdc357bbb5cd23167f50d838d6)
End of ad hoc announcement
About Spexis
Spexis is a clinical-stage biopharmaceutical company based in Allschwil,
Switzerland, focused on rare diseases and oncology. The current pipeline of
the company is a combination of two legacy companies, Polyphor AG and
EnBiotix, Inc. (Boston, MA, USA) which merged in December 2021. The combined
company has been renamed to Spexis AG and is trading on the SIX Swiss Exchange
under the symbol SIX:SPEX. For further information please visit:
www.spexisbio.com (http://www.spexisbio.com/) .
Disclaimer
This press release contains forward-looking statements which are based on
current assumptions and forecasts of Spexis management. Known and unknown
risks, uncertainties, and other factors could lead to material differences
between the forward-looking statements made here and the actual development,
in particular Spexis' results, financial situation, and performance. Readers
are cautioned not to put undue reliance on forward-looking statements, which
speak only of the date of this communication. Spexis disclaims any intention
or obligation to update and revise any forward-looking statements, whether as
a result of new information, future events or otherwise.
Additional features:
File: Spexis to announce FY2021 Financial Results
(https://eqs-cockpit.com/c/fncls.ssp?u=739492cdc357bbb5cd23167f50d838d6)
End of ad hoc announcement
Language: English
Company: Spexis AG
Hegenheimermattweg 125
4123 Allschwil
Switzerland
Phone: +41 61 567 1600
Fax: +41 61 567 1601
E-mail: info@spexisbio.com
Internet: www.spexisbio.com
ISIN: CH0106213793
Valor: SPEX
Listed: SIX Swiss Exchange
EQS News ID: 1297747
End of Announcement EQS News Service
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRAUKABRUUUORRR